Department of Haematology, St George's Hospital, Blackshaw Road, London, UK.
Expert Rev Hematol. 2010 Apr;3(2):217-25. doi: 10.1586/ehm.10.8.
Two different thrombopoietic drugs, romiplostim and eltrombopag, have completed Phase III trials in patients with immune-mediated thrombocytopenia and were observed to successfully improve platelet counts. This review will mostly focus on these two agents. We shall review their preclinical development as well as clinical trial results in immune-mediated thrombocytopenia. Also, we shall discuss their potential clinical use in thrombocytopenias associated with other medical conditions where reduction in platelet production is an integral part of disease manifestations.
两种不同的促血小板生成药物，罗米司亭和艾曲泊帕，已在免疫性血小板减少症患者中完成了 III 期临床试验，观察到它们能成功地提高血小板计数。本综述将主要关注这两种药物。我们将回顾它们在免疫性血小板减少症中的临床前开发和临床试验结果。此外，我们还将讨论它们在与血小板生成减少是疾病表现的一个组成部分的其他医学病症相关的血小板减少症中的潜在临床应用。
